PCP
MYGN icon

Perimeter Capital Partners’s Myriad Genetics MYGN Stock Holding History

Perimeter Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-131,811
Closed -$3.1M – 215
2013
Q3 		$3.1M Sell
131,811
-5,368
-4% -$153K 0.58% 77
2013
Q2 		$3.69M Buy
+137,179
New +$3.98M 0.71% 39

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perimeter Capital Partners's MYGN Position: Q4 2013 in Review

Perimeter Capital Partners sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 131,811 shares — an estimated $3.1M sold.

Perimeter Capital Partners first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $3.69M in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Perimeter Capital Partners reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Perimeter Capital Partners sold 131,811 Myriad Genetics shares in Q4 2013, an estimated $3.1M.
  • Perimeter Capital Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Perimeter Capital Partners's Myriad Genetics position peaked at $3.69M in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Perimeter Capital Partners's 13F filing for Q4 2013, filed 10 Feb 2014.